Gene Therapy: The Next-Generation Therapeutics and Their Delivery Approaches for Neurological Disorders.

IF 4.9 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Frontiers in genome editing Pub Date : 2022-01-01 DOI:10.3389/fgeed.2022.899209
Abhik Paul, Michael G Collins, Hye Young Lee
{"title":"Gene Therapy: The Next-Generation Therapeutics and Their Delivery Approaches for Neurological Disorders.","authors":"Abhik Paul,&nbsp;Michael G Collins,&nbsp;Hye Young Lee","doi":"10.3389/fgeed.2022.899209","DOIUrl":null,"url":null,"abstract":"<p><p>Neurological conditions like neurodevelopmental disorders and neurodegenerative diseases are quite complex and often exceedingly difficult for patients. Most of these conditions are due to a mutation in a critical gene. There is no cure for the majority of these neurological conditions and the availability of disease-modifying therapeutics is quite rare. The lion's share of the treatments that are available only provide symptomatic relief, as such, we are in desperate need of an effective therapeutic strategy for these conditions. Considering the current drug development landscape, gene therapy is giving us hope as one such effective therapeutic strategy. Consistent efforts have been made to develop gene therapy strategies using viral and non-viral vectors of gene delivery. Here, we have discussed both of these delivery methods and their properties. We have summarized the relative advantages and drawbacks of viral and non-viral vectors from the perspectives of safety, efficiency, and productivity. Recent developments such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated gene editing and its use <i>in vivo</i> have been described here as well. Given recent advancements, gene therapy shows great promise to emerge as a next-generation therapeutic for many of the neurodevelopmental and neurodegenerative conditions.</p>","PeriodicalId":73086,"journal":{"name":"Frontiers in genome editing","volume":"4 ","pages":"899209"},"PeriodicalIF":4.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272754/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in genome editing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fgeed.2022.899209","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Neurological conditions like neurodevelopmental disorders and neurodegenerative diseases are quite complex and often exceedingly difficult for patients. Most of these conditions are due to a mutation in a critical gene. There is no cure for the majority of these neurological conditions and the availability of disease-modifying therapeutics is quite rare. The lion's share of the treatments that are available only provide symptomatic relief, as such, we are in desperate need of an effective therapeutic strategy for these conditions. Considering the current drug development landscape, gene therapy is giving us hope as one such effective therapeutic strategy. Consistent efforts have been made to develop gene therapy strategies using viral and non-viral vectors of gene delivery. Here, we have discussed both of these delivery methods and their properties. We have summarized the relative advantages and drawbacks of viral and non-viral vectors from the perspectives of safety, efficiency, and productivity. Recent developments such as clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated gene editing and its use in vivo have been described here as well. Given recent advancements, gene therapy shows great promise to emerge as a next-generation therapeutic for many of the neurodevelopmental and neurodegenerative conditions.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基因治疗:神经系统疾病的新一代治疗方法及其传递途径。
神经发育障碍和神经退行性疾病等神经系统疾病非常复杂,对患者来说往往非常困难。这些情况大多是由于一个关键基因的突变。这些神经系统疾病中的大多数都无法治愈,而且疾病改善疗法的可用性相当罕见。大部分可用的治疗方法只能缓解症状,因此,我们迫切需要一种有效的治疗策略来治疗这些疾病。考虑到目前的药物发展前景,基因治疗作为一种有效的治疗策略给了我们希望。利用病毒和非病毒载体的基因传递开发基因治疗策略已经取得了一致的努力。在这里,我们讨论了这两种传递方法及其特性。我们从安全性、效率和生产力的角度总结了病毒载体和非病毒载体的相对优缺点。最近的发展,如聚集规律间隔短回文重复序列(CRISPR)/ cas9介导的基因编辑及其在体内的应用也在这里进行了描述。鉴于最近的进展,基因疗法显示出巨大的希望,成为许多神经发育和神经退行性疾病的下一代治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.00
自引率
0.00%
发文量
0
审稿时长
13 weeks
期刊最新文献
Towards functional maps of non-coding variants in cancer. Beyond the traditional distinctions of genome editing: evaluating a vulnerability framework. Knockout mutation in TaD27 enhances number of productive tillers in hexaploid wheat. Targeting DLBCL by mutation-specific disruption of cancer-driving oncogenes. The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1